Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 7–13

doi: 10.17219/acem/68290

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System

Elżbieta Lachert1,A,B,C,D,E,F, Jolanta Woźniak2,A,B,C,D,E,F, Jolanta Antoniewicz-Papis1,A,B,C,D,E,F, Agnieszka Krzywdzińska2,B,E, Jolanta Kubis1,B,C,D,E,F, Agata Mikołowska1,B,C,D,E,F, Magdalena Letowska1,B,C,D,E,F

1 Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Warszawa, Poland

2 Department of Diagnostics for Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland

Abstract

Background. Leukocytes in transfused blood components, particularly residual lymphocytes, have been shown to contribute to the occurrence of various adverse reactions. One of the most severe is transfusionassociated graft versus host disease (TA-GvHD) following transfusion of blood components contaminated with immunocompetent T lymphocytes. Irradiation is a routine method for protection against TA-GvHD. According to the literature, some pathogen reduction methods have also been proven effective for the inactivation of T lymphocytes, and so they may be considered as an alternative to irradiation.
Objectives. Comparison of CD69 antigen expression and the integrity of the leukocyte cellular membrane in stored platelet concentrates (PCs) following irradiation with the Gammacell 3000 Elan (Nordion Inc., Ottawa, Canada) and treatment with the Mirasol® Pathogen Reduction Technology (PRT) System (Terumo BCT, Lakewood, USA).
Material and Methods. The study included seven experiments. For each experiment we used 3 PCs, for Mirasol® PRT System treatment (M), for Gammacell 3000 Elan irradiation (R), and for the control (C). 7-amino-actinomycin D (7-AAD, Becton Dickinson, Franklin Lakes, USA) permeability was used to determine lymphocyte viability while CD69 antigen expression was the marker of lymphocyte activation. Analyses of 7-AAD and CD69 antigen expression were performed in a FACS Canto I flow cytometer (Becton Dickinson, USA).
Results. During 6 storage days, viable lymphocyte count decreased to 28% (p = 0.001) in the Mirasol® PRT System treated PCs and to 65% (p = 0.004) in the irradiated PCs. A statistically significant increase in CD69 expression in the irradiated PCs was observed; 1.3-fold on day 3 and 1.5-fold on day 6. In the Mirasol ® PRT System treated PCs, no statistically significant increase was observed.
Conclusion. The in vitro results suggest that the Mirasol® PRT System is as effective as irradiation due to donor leukocyte inactivation capacity.

Key words

blood component, leukocyte viability, CD69

References (21)

  1. Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang. 2008;95:85–93.
  2. Pogłód R. Transfusion-associated – Graft versus Host Disease (TA-GvHD). Acta Haematologica Polonica. 2009;40(2):425–434.
  3. Annual SHOT Report 2015. http://www.shotuk.org/wp-content/uploads/SHOT-2015-Annual-Report-Web-Edition-Final-bookmarked-1.pdf. Accessed September 14, 2016.
  4. Moroff G, Luban NLC. The irradiation of blood and blood components to prevent graft-versus-host disease: Technical issues and guidelines. Transfus Med Rev. 1997;11:15–26.
  5. Mintz PD, Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant. 2009;44:205–211.
  6. Fast LD, DiLeone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treat-ment in comparison to gamma irradiation. Transfusion. 2011;51:1397–1404.
  7. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment. Vox Sang. 2015;109:343–352.
  8. Luban NLC, Drothler D, Moroff G, Quinones R. Irradiation of platelet components: inhibition of lymphocyte proliferation assessed by limit-ing-dilution analysis. Transfusion. 2000;40:348–352.
  9. Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642–648.
  10. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: An in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293:127–142.
  11. Marschner S, Fast LD, Baldwin III WM, Slichter SJ, Goodrich RP. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion. 2010;50:2489–2498.
  12. Cazenave JP, Follea G, Bardiaux L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50:2362–2375.
  13. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2–/–γc–/– double knockout mice. Transfusion. 2006;46:1553–1560.
  14. Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang. 1994;66:14–17.
  15. Antoniewicz-Papis J, Dąbrowska A. Preparation of blood and blood components. In: Łętowska M, ed. Medical standards for collection, prepa-ration and distribution of blood and blood components. 3rd ed. Warszawa: Institute of Hematology and Transfusion Medicine; 2014:242–249.
  16. Lachert E, Kubis J, Dąbrowska A. Quality Assurance System in Blood Transfusion Service. In: Łętowska M, ed. Medical standards for collection, preparation and distribution of blood and blood components. 3rd ed. Warszawa: Institute of Hematology and Transfusion Medicine; 2014:91–92.
  17. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria In platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885.
  18. Picker SM, Steisel A, Gathof BS. Evaluation of white blood cell- and platelet-derived cytokine accumulation in MIRASOL-PRT-Treated plate-lets. Transfusion Medicine and Hemotherapy. 2009;36:114–120.
  19. Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: Mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion. 2009;49:2686–2699.
  20. Diacovo TG, Catalina MD, Siegelman MH, von Andrian UH. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. J Exp Med. 1998;187;197–204.
  21. Pόcsik É, Mihalik R, Gyόdi É, et al. Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product. Clin Exp Im-munol. 1990;82:102–107.
© Wroclaw Medical University